Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
about
Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 studyIncidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosisValidation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue.Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma.Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.Invariant natural killer T infiltration in neuroblastoma with favorable outcome.Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, anNeuroblastoma: clinical and biological approach to risk stratification and treatment.Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
P2860
Q33691441-1A87612C-ED6C-40D0-9E17-122D64AB83B2Q38635452-A939A55F-7FDC-4E51-B979-0F1D94EE2022Q38700629-35AD36B4-7FE7-4409-912A-2FB3EAD0B2BFQ40050078-0DFB77CA-EF8A-40F8-9AA0-7D0F94195B43Q44123857-6CCE1499-2F82-47E3-A1D9-5052823F58E0Q47771714-F9FCE45D-E721-481D-B8A9-6DC76FC6AF07Q47869615-AF05963A-334D-4C14-A106-49858BC33FE4Q49210694-540ABB2A-AA75-47D8-A324-97113A37AD81Q50091802-A448F468-0CCD-42AB-BDEA-CE840E9FD8A6Q50091814-A0B0E020-8C50-4581-9E20-676E6C7D875CQ50523001-C902C3B9-C3BC-426F-BCE6-72BB89888DFAQ52639269-D7A4482A-84A6-41DA-A9F7-09EBCE2DC51AQ55618874-20E5C28E-15A6-44A9-9A52-7D590B27D398Q58702896-12FA8E2F-168D-4BF4-AD67-81BEAF6A21E3
P2860
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Busulfan and melphalan versus ...... rm, open-label, phase 3 trial.
@en
type
label
Busulfan and melphalan versus ...... rm, open-label, phase 3 trial.
@en
prefLabel
Busulfan and melphalan versus ...... rm, open-label, phase 3 trial.
@en
P2093
P50
P1433
P1476
Busulfan and melphalan versus ...... arm, open-label, phase 3 trial
@en
P2093
Ana Forjaz de Lacerda
Andrew D J Pearson
Dominique Valteau-Couanet
Ellen Ruud
Geneviève Laureys
Gilles Vassal
Günter Schreier
Henrik Schroeder
Isaac Yaniv
Jean Michon
P304
P356
10.1016/S1470-2045(17)30070-0
P577
2017-03-02T00:00:00Z